12/21
07:42 am
nktr
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) [Yahoo! Finance]
Medium
Report
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) [Yahoo! Finance]
12/19
10:42 am
nktr
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]
Medium
Report
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]
12/19
10:36 am
nktr
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]
Medium
Report
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]
12/17
08:05 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.
12/17
07:06 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
High
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/16
01:43 pm
nktr
iShares MSCI EAFE Growth ETF declares semi-annual distribution of $1.8057 [Seeking Alpha]
Medium
Report
iShares MSCI EAFE Growth ETF declares semi-annual distribution of $1.8057 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI Indonesia ETF declares semi-annual distribution of $0.1615 [Seeking Alpha]
Medium
Report
iShares MSCI Indonesia ETF declares semi-annual distribution of $0.1615 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI Emerging Markets Min Vol Factor ETF declares semi-annual distribution of $0.9748 [Seeking Alpha]
Medium
Report
iShares MSCI Emerging Markets Min Vol Factor ETF declares semi-annual distribution of $0.9748 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI EAFE ETF declares semi-annual distribution of $1.7279 [Seeking Alpha]
Medium
Report
iShares MSCI EAFE ETF declares semi-annual distribution of $1.7279 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI EAFE Min Vol Factor ETF declares semi-annual distribution of $1.1733 [Seeking Alpha]
Low
Report
iShares MSCI EAFE Min Vol Factor ETF declares semi-annual distribution of $1.1733 [Seeking Alpha]
12/16
01:37 pm
nktr
Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript [Seeking Alpha]
Medium
Report
Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript [Seeking Alpha]
12/16
01:37 pm
nktr
iShares MSCI Denmark ETF declares semi-annual distribution of $1.5552 [Seeking Alpha]
Medium
Report
iShares MSCI Denmark ETF declares semi-annual distribution of $1.5552 [Seeking Alpha]
12/16
01:37 pm
nktr
iShares MSCI ACWI Low Carbon Target ETF declares semi-annual distribution of $3.3809 [Seeking Alpha]
Medium
Report
iShares MSCI ACWI Low Carbon Target ETF declares semi-annual distribution of $3.3809 [Seeking Alpha]
12/16
01:37 pm
nktr
iShares MSCI France ETF declares semi-annual distribution of $0.2281 [Seeking Alpha]
Medium
Report
iShares MSCI France ETF declares semi-annual distribution of $0.2281 [Seeking Alpha]
12/16
01:37 pm
nktr
iShares ESG Advanced MSCI EAFE ETF declares semi-annual distribution of $2.5043 [Seeking Alpha]
Neutral
Report
iShares ESG Advanced MSCI EAFE ETF declares semi-annual distribution of $2.5043 [Seeking Alpha]
12/16
01:07 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $120.00 to $135.00. They now have a "buy" rating on the stock.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $120.00 to $135.00. They now have a "buy" rating on the stock.
12/16
07:58 am
nktr
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata [Yahoo! Finance]
High
Report
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata [Yahoo! Finance]
12/16
07:30 am
nktr
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
High
Report
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
12/15
06:21 pm
nktr
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 [Yahoo! Finance]
High
Report
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 [Yahoo! Finance]
12/15
06:00 pm
nktr
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
High
Report
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
12/5
06:37 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/5
06:00 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26
09:11 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.
11/24
07:02 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/19
07:43 pm
nktr
How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]
Medium
Report
How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]